CAR-T Cell Therapy for Malignant Melanoma: Current Landscape and Future Directions

Chimeric Antigen Receptor (CAR) T cells are modified T cells that have been genetically engineered to produce chimeric antigen receptors. Chimeric antigen receptors allow the T cells to identify and destroy specific cancer cells more efficiently, thus making CAR-T cell therapy a transformative immunotherapy. CAR-T cells have been tested and used as a treatment for leukemia and lymphomas and have shown high success and remission rates for decades. In this review, the modification and use of this therapy for solid cancers, specifically malignant melanomas, as well as its effectiveness, is explored. Studies work on discovering the most effective modifications of CAR-T cells, including inhibiting certain growth factors and testing numerous generations of the intracellular signaling domain. CAR-T cells are shown to be partially effective in certain studies and have been attributed to reduced recurrence rates in patients. The heterogeneity of melanoma cancers, antigen loss, and toxicities associated with the therapy limit the viability and effectiveness of the current treatment model. As such, the effectiveness, feasibility, and safety of CAR-T cell therapies in melanoma treatment is inconclusive as of now. More research is needed in overcoming the limitations of this therapy in order to determine its effectiveness as a treatment for melanoma cancers. Additionally, future research should focus on testing combinations of modifications of CAR-T cells, instead of testing the modification of only one component, in order to accelerate the understanding of whether this therapy is effective for treating melanomas, and if so, how it could best be used to increase efficiency while combating toxicities and limitations.